Cell Biotech Co., Ltd.
Financials
Valuation Metrics
Cell Biotech Co., Ltd.'s Market Cap is ₩1494B. At end of 2025 it was ₩1232B. Ranked #993 of 2,436 in KR market (top 41%), #489 of 1,649 on KOSDAQ (top 30%), #118 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 149.37B KRW | KR#993/2,436 Sec#118/234 |
| Revenue | 56.49B KRW | KR#1,712/2,436 Sec#116/234 |
| Net Income | 13.41B KRW | KR#792/2,436 Sec#53/234 |
| Total Assets | 143.29B KRW | KR#1,502/2,436 Sec#119/234 |
| Net Assets | 133.03B KRW | KR#1,186/2,436 Sec#94/234 |
| Employees | 123 | KR#1,476/2,436 Sec#117/234 |
| Value | ||
| P/E | 11.14x | KR#776/2,436 Sec#42/234 |
| P/B | 1.12x | KR#1,582/2,436 Sec#106/234 |
| PEG | 0.07x | KR#325/2,436 Sec#17/234 |
| P/S | 2.64x | KR#1,963/2,436 Sec#117/234 |
| EV/EBITDA | 12.59x | KR#753/2,436 Sec#41/234 |
| FCF Yield | 5.36% | KR#844/2,436 Sec#41/234 |
| Profitability | ||
| ROE | 10.08% | KR#505/2,436 Sec#32/234 |
| ROA | 9.36% | KR#233/2,436 Sec#19/234 |
| Op. Margin | 17.24% | KR#208/2,436 Sec#20/234 |
| Revenue Growth | 30.00% | KR#475/2,436 Sec#44/234 |
| Earnings Growth | 158.57% | KR#304/2,436 Sec#20/234 |
| Financial Health | ||
| Debt Ratio | 107.71% | KR#386/2,436 Sec#54/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | 8.00B KRW | KR#772/2,436 Sec#44/234 |
| Cash | 26.72B KRW | KR#1,066/2,436 Sec#72/234 |
| Current Ratio | 10.50x | KR#93/2,436 Sec#24/234 |
| Net Debt/EBITDA | -2.74x | KR#224/2,436 Sec#12/234 |
| Dividend | ||
| Div. Yield | 3.93% | KR#470/2,436 Sec#16/234 |
| Div. Growth | 33.33% | KR#315/2,436 Sec#16/234 |
| Performance | ||
| 1Y Return | 20.84% | KR#422/2,436 Sec#36/234 |
| 1M Return | 4.27% | KR#526/2,436 Sec#44/234 |
| From 52W High | -14.11% | KR#96/2,436 Sec#4/234 |
| 1Y MDD | -19.18% | KR#38/2,436 Sec#2/234 |
| Trading | ||
| Volume | 8,545 shares | KR#2,162/2,436 Sec#214/234 |
| Foreign Own. | 4.33% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,426 KRW | KR#489/2,436 Sec#34/234 |
| BPS | 19,438 KRW | KR#521/2,436 Sec#36/234 |
Company Info
Cell Biotech was established in 1995 for the research and manufacturing of probiotic lactic acid bacteria products and was listed on KOSDAQ in 2002. The company offers a one-stop solution from probiotic strain development to finished product manufacturing and distribution, achieving the top export position in 2023. By leveraging its dual-coating technology and launching personalized 'Cellbiom' products, Cell Biotech is expanding its business scope and product competitiveness. Cell Biotech is headquartered in Gimpo-si, Gyeonggi-do.